Thank you. Operator. Good morning, and a warm welcome to Egetis Therapeutics webcast for the quarter three report and results. For those who haven't had the privilege to meet before, my name is Nicklas Westerholm, and I am the CEO of the company. With me today, I also have our CFO, Yilmaz Mahshid, Karl Hård, our Head of Investor Relations and Business Development, and Henrik Krook, our Head of Commercial Operations globally. What we were planning to cover today are updates on several important milestones delivered during the quarter. We will touch upon the progress of our Marketing Authorization application for Emcitate with the EMA, and the guidelines for Diagnosis and Management of MCT8 deficiency issued in July by the European Thyroid Association. The new data was published through an abstract concerning survival. The data was presented at the 46th Annual Meeting of the European Thyroid Association in September. The ReTRIACt trial status is obviously important, recognizing that it is a pivotal randomized controlled study for the US submission. We'll also touch upon the patent application we submitted to the US Patent and Trademark Office regarding the process of preparation of tiratricol, and also touch upon the news that will feature during October and early November, which was the directed share issue of around 30 million USD. We'll then move into a financial update from Yilmaz Mahshid and then subsequently move into Q&A from the audience. So starting off with the marketing authorization application for the approval in the European Union, we are very pleased to call out that we remain on track according to the EMA's stipulated timelines. As many of you would know, the marketing authorization application was submitted in October last year, and subsequently, we received the 120-day questions in February, which we responded to in August. Subsequent to that, as per the stipulated timelines, we received on the 17th of October, the day 180 questions, and planned to respond to these by November 12th, i.e. beginning of next week. According to EMA's published procedural timelines. Published procedural timelines. Subsequent to that. The ball is, of course, in the EMA's court, but we are looking forward to a CHMP opinion towards the end of this year or early next year. Along the lines of Europe, we also had some guidelines that were issued in July. The guidelines were issued by the European Thyroid Association (ETA) covering diagnosis and treatment of Emcitate deficiency, among others. This is somewhat unusual, recognizing that Emcitate deficiency is an ultra rare condition with no therapy approved to date. These guidelines recommend the use of tiratricol or Emcitate as a long-term therapy for all patients with MCT8 deficiency, but also for certain patients with a different indication, such as resistance to thyroid hormone beta (RTH-beta). This is, of course, valuable for us moving forward; it will be important for commercialization in Europe, where clear guidelines now exist and will also support the management of this disease. Page two.
Some new data that was published in more detail. So this data derives from a retrospective research study by the Erasmus Medical Center in Rotterdam, where they investigated the effects of tiratricol on mortality in patients with MCT8 deficiency. The abstract was published ahead of the European Thyroid Association meeting, and the data presented is extremely valuable for us. It illustrates that tiratricol treatment had an approximately three times lower risk of all-cause mortality, which is, of course, very much to our benefit. Moving ahead, especially when it comes to payer interactions in Europe, as well as the forthcoming US drug application. On top of that, a peer-reviewed publication is in progress, which will hopefully be published at the beginning of next year. Turning our attention to the ReTRIACt study, where we have had better progress in quarter three compared to previous quarters, which is very important to underline. As a reminder, this study was agreed upon with the US FDA. A pivotal, randomized, placebo-controlled study in at least 16 evaluable patients with MCT8 deficiency to support the NDA. We all recognize, and we need to be humble, that the recruitment in previous quarters hasn't been up to our expectations and to increase the recruitment study during the summer, we added three additional clinical study sites. Commercial study sites, which were opened in July in the US, one in Texas, one in Georgia, and one in North Carolina. So at this moment, we have six study sites open, two in Europe and four in the US. The current study status includes the two patients we expected to be randomized, which we highlighted in our quarter two report. Furthermore, the six patients planned for screening, which were also mentioned in the quarter two report, resulted in four new patients that are now in the running period. So in total, we now have 17 patients included, of which eight patients are available and four patients are in the so-called running period. Please note here that, as with any clinical study, there will be a few drop-outs and hence not all patients included will be randomized. Going forward, we have more than ten eligible patients identified and remaining for recruitment, of which a couple of patients are already scheduled for screening in the coming weeks. As previously communicated, we have full focus on the recruitment for the ReTRIACt study, and we will update the market as soon as the recruitment for the study is closed. At that point, we'll also be able to provide information on expected top-line results and when we plan to submit a new drug application. Moving on to our patent application. As many of you know, today it holds orphan drug designation. ODD for Emcitate for the treatment of Emcitate deficiency, as well as RTH-beta, both in the US and Europe. That provides marketing exclusivity of seven years in the US and ten years in Europe, respectively, from the dates of regulatory approval. We were very pleased with the submission of our first patent application concerning processes of preparation for tiratricol and, in layman's terms, manufacturing patents. If granted, this would be a significant patent and important for us. Generally, the exclusivity term of a new patent is 20 years from the date on which the patent application for the specific patent in question was filed in the US. Let's turn our attention to our directed share issue. We announced the share issue. The directed share issue occurred on the 30th of September. And this was a directed share issue for approximately 30 million USD, or 300 million Swedish kronor. The directed share issue was oversubscribed and included both existing and new international and Swedish institutional investors. We are very proud, considering the challenging market conditions, that we executed this. The subscription price was at market value, and more importantly, the directed share issue was led by Frazier Life Sciences with 10 million, or roughly a third of the share issue, executed on their behalf. So with that, let's turn our attention to the financials for the quarter. And I hand over to our CFO, Yilmaz Mahshid. Please go ahead.